38 – HIV Drug Resistance

Speaker: Michael Saag, MD

IDBR INFECTIOUS DISEASE BOARD REVIEW AUGUST 17-21, 2024

HIV Drug Resistance

Michael S. Saag, MD
Professor of Medicine
University of Alabama at Birmingham

7/1/2024

IDBR INFECTIOUS DISEASE BOARD REVIEW AUGUST 17-21, 2024

- **Disclosures of Financial Relationships with Relevant Commercial Interests**
  - **None**

How does resistance happen?







©2024 Infectious Disease Board Review, LLC









Resistance Testing

- Genotypic resistance test
  - Perform test that gives mutations in viral genes
- Phenotypic resistance test
  - Perform test that describes growth of virus in the presence of anti-HIV drugs
- Limitations:
  - Cannot detect minority species (< 10% of viral population)

Key Issues in HIV Resistance

Easily Tested

- Specific Mutations
- Cross – resistance
- Prevalence of resistance at baseline

Tough to Test

- Definition of Phenotypes
- Complex resistance patterns
- Genetic Barrier
- Nuances of Resistance
- Relationship between Pk and Pd

12

©2024 Infectious Disease Board Review, LLC

38 – HIV Drug Resistance

Speaker: Michael Saag, MD

HIV Drug Resistance Testing

- Current guidelines recommend an HIV genotype as part of screening BEFORE ART is started.
- Following failure of 1st or 2nd regimens, HIV genotype is recommended to use with the history to choose the optimal next regimen.
- Following failure of 3rd and subsequent regimens, both HIV genotype AND HIV phenotype should be sent.
- If there is discordance between genotype and phenotype results, use the geno result (more sensitive).
- NOTE WELL: Resistance mutations accrued from an earlier regimen MAY NOT be detected by tests obtained at the time of the current failing regimen

HIV-1 Genome



Mutation Nomenclature

Codon (position)
PR = 1-99 amino acids
RT = 1-560 amino acids

M184V

Mutation Nomenclature

Codon (position)
PR = 1-99 amino acids
RT = 1-560 amino acids

M184V

Wild-type amino acid (consensus)

Mutant amino acid

Table 1. Amino acids and their abbreviations.

Alanine	A
Cysteine	C
Aspartate	D
Glutamate	E
Phenylalanine	F
Glycine	G
Histidine	H
Isoleucine	I
Lysine	K
Leucine	L
Methionine	M
Asparagine	N
Proline	P
Glutamine	Q
Arginine	R
Serine	S
Threonine	T
Valine	V
Tryptophan	W
Tryosine	Y

Everything You Need to Know About Nucleoside Analog Resistance in One Slide!

Mutation	Selected by	Effects on other NRTIs
184V	3TC, FTC	- Loss of susceptibility to 3TC, FTC - ↓ susceptibility to ABC, ddI (clinically insignificant) - Delayed TAMS and ↑ susceptibility to AZT, d4T, TDF
~~TAMs~~	AZT, d4T	- ↓ susceptibility to all NRTIs based on number of TAMs - More resistance with 41/210/215 than 67/70/219 pathway
~~151M, 69ins~~	AZT/ddI, ddI/d4T	- Resistance to all NRTIs - T69ins: TDF resistance
K65R	TDF, ABC, ddI	- Variable ↓ susceptibility to TDF, ABC, ddI (and 3TC, FTC) - ↑ susceptibility to AZT
~~74V~~	ABC, ddI	- ↓ susceptibility to ABC, ddI - ↑ susceptibility to AZT, TDF
~~44D, 118I~~	AZT, d4T	-Increase NRTI resistance (with 41/210/215 pathway)

CASE 1

- 25 year old man presents with newly diagnosed HIV
- Had an episode c/w acute seroconversion syndrome 4 months ago
- Initial HIV RNA 40,000; CD4 443 cells/ul
- He wants to start ARV therapy

©2024 Infectious Disease Board Review, LLC

38 – HIV Drug Resistance

Speaker: Michael Saag, MD

Question #1

A baseline genotype is ordered that shows an M184V mutation. Which of the following drugs will have reduced susceptibility with this mutation?

A. Efavirenz
B. Zidovudine
C. Tenofovir
D. Etravirene
E. Emtricitabine



CASE 2

- 34 yo woman diagnosed with HIV 10 years ago
- Initially presented with PJP
- Initial Lab values
  - CD4 82 cells/uL
  - VL 106,000 c/mL
- Started on TDF / FTC / EFV (FDC)
- Did well for a while, then the regimen failed

Question #2

The genotype shows an M184V and K65R mutations. Which nRTI drugs would you include?

A. ZDV
B. TDF
C. ddI
D. ABC



©2024 Infectious Disease Board Review, LLC

Non-nucleoside Reverse Transcriptase (NNRTI) Mutations

- K103N is the signature mutation for efavirenz (EFV).
- Y181C is the signature mutation for nevirapine (NVP).
- Older NNRTIs, efavirenz and nevirapine, have low genetic barriers (require only 1 mutation for resistance) and are **COMPLETELY** cross-resistant to one another.
- Newer NNRTIs, etravirine (ETR), rilpivirine (RPV), and doravirine (DOR) have higher barriers to resistance (require >1 mutation for resistance).
- K103N has no effect on etravirine susceptibility.
- Rilpivirine failure is associated with E138K, K101E, and/or Y181C and consequently, resistance to ALL NNRTIs.

CASE 3

- 34 yo woman diagnosed with HIV three years ago
- Initially presented with PJP
- Initial Lab values
  - CD4 82 cells/uL
  - VL 106,000 c/mL
- She was treated with TDF / FTC / ELV/ Cobi (FDC)
- The regimen failed after 12 months

Question #3

Which of the following mutations indicate high level resistance to elvategravir ?

A. Q148R
B. L68I
C. L68V
D. K67N
E. K65R

InSTI Resistance Mutations



Lenacapavir Resistance Mutations

MUTATIONS IN THE CAPSID GENE ASSOCIATED WITH RESISTANCE TO CAPSID INHIBITORS

	L 56	M 66	Q 67	K 70	N 74	A 105	T 107
Lenacapavir[31]	I	I	H	N S R	D S	T	N

Case #4

PREVIEW QUESTION

- 34 yo MSM receiving CAB IM q 2 months for pre-exposure prophylaxis for last 6 months
- Asymptomatic
- HIV Ag/Ab test negative
- Routine screening: HIV RNA 6.1 c/ml

©2024 Infectious Disease Board Review, LLC

38 – HIV Drug Resistance

Speaker: Michael Saag, MD

Question #4

PREVIEW QUESTION

Which of the following ARV resistance mutations is most likely in this setting?

A. S147G
B. N155H
C. Y143R
D. E92Q
E. K65R

Case Study: Confirmation of Infection



InSTI Resistance Mutations



CASE 4

- 34 yo woman diagnosed with HIV 22 years ago
- Initially presented with PJP
- Initial Lab values
  - CD4 82 cells/uL
  - VL 106,000 c/mL
- Has been on multiple regimens over the years

Question #5

What is the likelihood she has high level resistance (< 2 active drugs available) ?

A. < 1 %
B. 1 - 5 %
C. 5 -10%
D. 10 - 20%
E. > 20%

Prevalence of Patients with Limited Treatment Options



©2024 Infectious Disease Board Review, LLC

38 – HIV Drug Resistance

Speaker: Michael Saag, MD

Virologic Success in Those with or without LTO



Common Mutations To Memorize

• **M184V/I**	3TC and FTC
• M41L, D67N, K70R, L210W, T215Y, K219Q	"TAMS"
4 or more thymidine-analog mutations (TAMS) affect all approved nucleosides	
• **K65R**	tenofovir
• Q151M, 69SSS	multi-NRTI
• **K103N**	EFV (and NVP)
retains susceptibility to etravirine	
• **Y181C**	NVP and other NNRTI
• E138K, K101E	RPV and other NNRTI
• I50L	ATV
• **N155H, Q148H/R/K**	RAL and EVG
• **Y143C**	RAL
• **R263K**	DTG

Summary

- High concern about resistance testing on Board Exams
- Difficult to create test questions that do not require complex interpretation, have a single best answer, or are not 'multiple true-false'
- Knowing common mutations and their role is a good way to prepare for the exam

39



©2024 Infectious Disease Board Review, LLC